(Q46147410)

English

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

scientific article published on 26 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

author name string

M P Escalón

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

A Stefanovic

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

A Venkatraman

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

D Pereira

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

E S Santos

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

M Goodman

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

J J Byrnes

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

H F Fernandez

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

language of work or name

0 references

publication date

26 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

44

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

89-96

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

https://scigraph.springernature.com/pub.10.1038/bmt.2008.429

0 references

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.429

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2008.429

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19169287

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46147410&oldid=2094971794"